Literature DB >> 16795069

Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.

Jonathan B McHugh1, Dafydd G Thomas, Joseph M Herman, Michael E Ray, Laurence H Baker, N Volkan Adsay, Raja Rabah, David R Lucas.   

Abstract

BACKGROUND: Craniofacial osteosarcoma differs from long bone osteosarcoma in that patients are older, tumors are often low grade, and prognosis is more favorable. Although most are sporadic, some tumors occur in association with prior radiation therapy. The purpose of the current study was to compare clinicopathologic and prognostic features of primary and radiation-associated osteosarcoma.
METHODS: The study group consisted of 15 primary and 6 radiation-associated osteosarcomas. Clinical and follow-up data were obtained in every case. Tissue microarrays were immunohistochemically stained for p53, pRB, Ki-67 (MIB-1), and ezrin. DNA was sequenced for TP53 mutations.
RESULTS: All radiation-associated osteosarcomas were high grade and half were fibroblastic. In contrast, 47% of primary craniofacial osteosarcomas were high grade and only 1 was fibroblastic. All radiation-associated osteosarcomas recurred, half the patients died of disease, 2 were alive with unresectable tumors, whereas only 1 was alive without disease. In contrast, 80% of patients with primary tumors were alive without disease, 33% had local recurrences, and 13% died of disease. Radiation-associated tumors overexpressed p53 more often (33% vs. 13%), more often had TP53 mutations (33% vs. 8%), had higher proliferative activity (67% vs. 0% showing >50% MIB-1 staining), and expressed ezrin more frequently (83% vs. 40%) than primary tumors. Compared with a control group of 24 high- and 7 low-grade primary extremity osteosarcomas, radiation-associated tumors marked as the high-grade tumors.
CONCLUSIONS: Craniofacial radiation-associated osteosarcomas are high-grade tumors that behave more aggressively than most primary craniofacial osteosarcomas. In addition, they demonstrate higher expression rates of adverse prognostic indicators, further highlighting the distinction. Copyright 2006 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795069     DOI: 10.1002/cncr.22019

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

1.  Prognostic role of cytovillin expression in patients with osteosarcoma: a meta-analysis.

Authors:  Shibing Guo; Rui Bai; Wei Zhao; Yuxin Wang; Zhenqun Zhao; Wei Feng
Journal:  Tumour Biol       Date:  2014-01

Review 2.  Adolescent and Young Adult Oral Maxillofacial Tumors: A Single-Institution Case Series and Literature Review.

Authors:  Anil P George; Michael R Markiewicz; Steven Garzon; Daniel K Choi
Journal:  J Adolesc Young Adult Oncol       Date:  2019-12-20       Impact factor: 2.223

3.  Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Authors:  Lara E Davis; Vanessa Bolejack; Christopher W Ryan; Kristen N Ganjoo; Elizabeth T Loggers; Sant Chawla; Mark Agulnik; Michael B Livingston; Damon Reed; Vicky Keedy; Daniel Rushing; Scott Okuno; Denise K Reinke; Richard F Riedel; Steven Attia; Leo Mascarenhas; Robert G Maki
Journal:  J Clin Oncol       Date:  2019-04-23       Impact factor: 44.544

Review 4.  Canine and murine models of osteosarcoma.

Authors:  Jessica Beck; Ling Ren; Shan Huang; Erika Berger; Kathleen Bardales; Joshua Mannheimer; Christina Mazcko; Amy LeBlanc
Journal:  Vet Pathol       Date:  2022-03-26       Impact factor: 3.157

5.  Radiation-induced cancer after radiotherapy for non-Hodgkin's lymphoma of the head and neck: a retrospective study.

Authors:  Kazuma Toda; Hitoshi Shibuya; Keiji Hayashi; Fumio Ayukawa
Journal:  Radiat Oncol       Date:  2009-07-10       Impact factor: 3.481

Review 6.  Soft Tissue Special Issue: Gnathic Fibro-Osseous Lesions and Osteosarcoma.

Authors:  Meera Hameed; Andrew E Horvai; Richard C K Jordan
Journal:  Head Neck Pathol       Date:  2020-01-16

7.  Osteosarcoma: A Comparison of Jaw versus Nonjaw Localizations and Review of the Literature.

Authors:  H van den Berg; W H Schreuder; J de Lange
Journal:  Sarcoma       Date:  2013-07-15

Review 8.  Correlations of ezrin expression with pathological characteristics and prognosis of osteosarcoma: a meta-analysis.

Authors:  Da-Hang Zhao; Jiang Zhu; Wen-Bo Wang; Feng Dong; Qiao Zhang; Hong-Wu Fan; Jing-Zhe Zhang; Yong-Ming Wang
Journal:  ScientificWorldJournal       Date:  2014-11-27

9.  Genetically engineered mouse models and human osteosarcoma.

Authors:  Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley
Journal:  Clin Sarcoma Res       Date:  2012-10-04

Review 10.  Advanced therapeutic strategy for radiation-induced osteosarcoma in the skull base: a case report and review.

Authors:  Shoko Merrit Yamada; Yudo Ishii; So Yamada; Shigehiko Kuribayashi; Shinichiro Kumita; Akira Matsuno
Journal:  Radiat Oncol       Date:  2012-08-10       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.